Use of recommended medications after myocardial infarction in Austria
Authors:
- Wolfgang C. WinkelmayerWWWolfgang C. Winkelmayer
- For The Pharmacoeconomics Advisory Council Of The Austrian Sickness FundsFFFor The Pharmacoeconomics Advisory Council Of The Austrian Sickness Funds
Open Access
- 7 December 2007
- journal article
- pharmaco epidemiology
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 23 (2) , 153-162
Abstract
Guidelines recommend long-term use of beta-blockers (BB), statins, and angiotensin-converting-enzyme-inhibitors or angiotensin-receptor-blockers (ACEI/ARB) after myocardial infarction (MI), but data on their use after discharge are scarce. From Austrian sickness funds claims, we identified all acute MI patients who were discharged within 30 days and who survived ≥120 days after MI in 2004. We ascertained outpatient use of ACEI/ARBs, BBs, statins, and aspirin from all filled prescriptions between discharge and 120 days post MI. Comorbidities were ascertained from use of indicator drugs during the preceding year. Multivariate logistic regression was used to evaluate the independent determinants of study drug use. We evaluated 4,105 MI patients, whose mean age was 68.8 (±13.2) years; 59.5% were men. Within 120 days after MI, 67% filled prescriptions for ACE/ARBs, 74% for BBs, and 67% for statin. While 41% received all these classes and 34% two, 25% of patients received only one or none of these drugs. Older age and presence of severe mental illness were associated with lower use of all drug classes. Diabetics had greater ACEI/ARB use. Fewer BBs were used in patients with obstructive lung disease. Statin use was lower in patients using treatment for congestive heart failure (all P < 0.001). We conclude that recommended medications were underused in Austrian MI survivors. Quality indicators should be established and interventions be implemented to ensure maximum secondary prevention after MI.Keywords
This publication has 42 references indexed in Scilit:
- Survival of patients discharged after acute myocardial infarction and evidence-based drug therapyEuropean Journal of Epidemiology, 2007
- Angiotensin inhibition after myocardial infarction: Does drug class matter?Journal of General Internal Medicine, 2006
- Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysisClinical Therapeutics, 2005
- 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for cliniciansNature Clinical Practice Cardiovascular Medicine, 2005
- Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of CardiologyEuropean Heart Journal, 2004
- Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsAmerican Heart Journal, 2004
- Hospital-Level Performance ImprovementMedical Care, 2004
- Regional variation in the treatment and outcomes of myocardial infarction: investigating New England’s advantageAmerican Heart Journal, 2003
- Cost effectiveness of ramipril treatment for cardiovascular risk reductionHeart, 2001
- Costs and Effectiveness of Routine Therapy with Long-Term Beta-Adrenergic Antagonists after Acute Myocardial InfarctionNew England Journal of Medicine, 1988